4//SEC Filing
Galligan Andrew H 4
Accession 0001567619-20-000906
CIK 0001444380other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 6:59 PM ET
Size
8.8 KB
Accession
0001567619-20-000906
Insider Transaction Report
Form 4
NEVRO CORPNVRO
Galligan Andrew H
VP of Finance , CFO
Transactions
- Exercise/Conversion
Common Stock
2020-01-08$63.23/sh+17,718$1,120,309→ 71,208 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-08−17,718→ 0 totalExercise: $63.23Exp: 2025-11-30→ Common Stock (17,718 underlying) - Sale
Common Stock
2020-01-08$120.11/sh−17,718$2,128,086→ 53,490 total
Footnotes (4)
- [F1]Includes 16,773 restricted stock units.
- [F2]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]Fully vested.
Documents
Issuer
NEVRO CORP
CIK 0001444380
Entity typeother
Related Parties
1- filerCIK 0001417976
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 6:59 PM ET
- Size
- 8.8 KB